Alan B. Sandler
CIK 1835966 · Chief Development Officer · last filed 2026-10-01
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
RVMD price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
323 ALLERTON AVE
SOUTH SAN FRANCISCO, CA 94080
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RVMD | Chief Development Officer | 52,559 | $183.90 | $9.67M | -$1.34M | 2 | 2026-10-01 |
| ALXO | Chief Medical Officer | — | $1.13 | — | $0 | 5 | 2026-01-21 |
| Elevation Oncology, Inc. (ELEV) Delisted | Director | — | $0.36 | — | $0 | 4 | 2025-07-24 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | Chief Medical Officer | 17,021 | $58.70 | $999.1K | $0 | 4 | 2024-01-23 |
| ZLAB | Head of Global Dev., Oncology | 28,985 | $24.34 | $705.5K | $0 | 4 | 2022-06-27 |
Recent Filings · Page 2 of 3
21 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-08-07 | ALXO | Grant (A) | — | $0 | EDGAR |
| 2024-06-17 | Elevation Oncology, Inc. (ELEV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-03-04 | Elevation Oncology, Inc. (ELEV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-01-23 | Mirati Therapeutics, Inc. (MRTX) Delisted | Disp (D) | −79,865 | $0 | EDGAR |
| 2024-01-03 | Mirati Therapeutics, Inc. (MRTX) Delisted | Grant (A) | +17,021 | $1000.0K | EDGAR |
| 2023-08-10 | Mirati Therapeutics, Inc. (MRTX) Delisted | Grant (A) | +22,297 | $825.0K | EDGAR |
| 2022-11-08 | Mirati Therapeutics, Inc. (MRTX) Delisted | Grant (A) | +40,000 | $0 | EDGAR |
| 2022-06-27 | ZLAB | Grant (A) | — | $0 | EDGAR |
| 2022-04-05 | ZLAB | Mixed | +1,060 | $0 | EDGAR |
| 2021-12-03 | ZLAB | Tax (F) | −2,075 | -$147.8K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.